Search - tctmd.com

Displaying 1 - 20 of 99

Sort: Relevancy | Date

News Conference News TCT 2016

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

Shelley Wood

November 07, 2016

News Conference News TCT 2016

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

Yael L. Maxwell

October 31, 2016

Presentation TCT 2016

TCT 66: Effects of Dual Antiplatelet Therapy Cessation Among Patients With Diabetes Mellitus After PCI With DES

Presenter: Sorin J. Brener, Jean-François Tanguay, Michela Faggioni

October 31, 2016

Presentation TCT 2016

TCT 5: Risks and Benefits of Dual Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery: Insights From the ACUITY Trial

Presenter: Dimitrios Alexopoulos, Laurent Bonello, Ramin Ebrahimi

October 31, 2016

News Conference News TCT 2016

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

Todd Neale

October 31, 2016

News Conference News TCT 2016

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Michael O'Riordan

October 30, 2016

News Conference News TCT 2016

DES With Biodegradable Polymers Stand Up Well Against Durable-Polymer Stents in the Short Term

Todd Neale

October 30, 2016

News Conference News TCT 2015

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Yael L. Maxwell

October 15, 2015

News Conference News TCT 2015

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

Todd Neale

October 14, 2015

News Conference News TCT 2015

LEADERS FREE: Drug-Coated Stent Bests BMS in High-Risk PCI Patients

Yael L. Maxwell

October 14, 2015

Presentation TCT 2015

TCT 82: Single Versus Dual Antiplatelet Therapy in Transcatheter Aortic Valve Replacement A Meta-analysis of Safety and Efficacy Outcomes

Presenter: Lisa K. Jennings, Neal S. Kleiman, Rhanderson Cardoso

October 13, 2015

Presentation TCT 2015

TCT 81: Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable-Polymer Sirolimus-Eluting Stent A Randomized Substudy of the I-LOVE-IT 2 Trial

Presenter: Lisa K. Jennings, Neal S. Kleiman, Yaling Han

October 13, 2015

Presentation TCT 2015

TCT 76: Six Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Biodegradable-Polymer Sirolimus-Eluting Stents for Bifurcation Lesions Insights From the I-LOVE-IT 2 Trial

Presenter: Lisa K. Jennings, Neal S. Kleiman, Bo Xu

October 13, 2015

News Conference News TCT 2015

Safety, Efficacy Endpoints Must Be Balanced in Clinical Trials

October 13, 2015

News Conference News TCT 2015

Discussion Highlights Merits, Limitations of Small Trials

Yael L. Maxwell

October 13, 2015

News Conference News TCT 2015

CENTURY II: Bioresorbable-Polymer DES Safe, Effective at 2 Years

October 13, 2015

Presentation TCT 2015

How Did We Manage This Patient?

Presenter: Paul A. Gurbel, Daniel I. Simon, Thomas D. Stuckey

October 12, 2015

Presentation TCT 2015

Case 3: Hot ACS and a History of Possible Aspirin Anaphylaxis

Presenter: Paul A. Gurbel, Daniel I. Simon, Thomas D. Stuckey

October 12, 2015

Presentation TCT 2015

Case 2: How Did We Manage This Patient?

Presenter: Paul A. Gurbel, Daniel I. Simon, Michael S. Lee

October 12, 2015

Presentation TCT 2015

Case 2: A Patient With Cardiac Arrest and ST-Segment Elevation

Presenter: Paul A. Gurbel, Daniel I. Simon, Michael S. Lee

October 12, 2015

Advertisement

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

TCT 66: Effects of Dual Antiplatelet Therapy Cessation Among Patients With Diabetes Mellitus After PCI With DES

TCT 5: Risks and Benefits of Dual Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery: Insights From the ACUITY Trial

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

DES With Biodegradable Polymers Stand Up Well Against Durable-Polymer Stents in the Short Term

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

LEADERS FREE: Drug-Coated Stent Bests BMS in High-Risk PCI Patients

TCT 82: Single Versus Dual Antiplatelet Therapy in Transcatheter Aortic Valve Replacement A Meta-analysis of Safety and Efficacy Outcomes

TCT 81: Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable-Polymer Sirolimus-Eluting Stent A Randomized Substudy of the I-LOVE-IT 2 Trial

TCT 76: Six Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Biodegradable-Polymer Sirolimus-Eluting Stents for Bifurcation Lesions Insights From the I-LOVE-IT 2 Trial

Safety, Efficacy Endpoints Must Be Balanced in Clinical Trials

Discussion Highlights Merits, Limitations of Small Trials

CENTURY II: Bioresorbable-Polymer DES Safe, Effective at 2 Years

How Did We Manage This Patient?

Case 3: Hot ACS and a History of Possible Aspirin Anaphylaxis

Case 2: How Did We Manage This Patient?

Case 2: A Patient With Cardiac Arrest and ST-Segment Elevation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content